Abstract

We describe the initial results of Emicizumab prophylaxis in twins diagnosed with severe Hemophilia A and inhibitors with intron 22 inversion. Prophylaxis was initiated in both the twins showing high annual bleed rate and difficult venous access. The treatment resulted in zero spontaneous bleeds and there were no adverse events.